PARP inhibitors: the race is on von Brown, Jessica S, Kaye, Stan B, Yap, Timothy A

Volltext

Beyond chemotherapy: targeted therapies in ovarian cancer von Yap, Timothy A., Carden, Craig P., Kaye, Stan B.

Volltext

Ovarian cancer: strategies for overcoming resistance to chemotherapy von Agarwal, Roshan, Kaye, Stan B.

Volltext

Combining Antiangiogenics to Overcome Resistance: Rationale and Clinical Experience von MORENO GARCIA, Victor, BASU, Bristi, MOLIFE, L. Rhoda, KAYE, Stan B

Volltext

The role of targeted therapy in ovarian cancer von Banerjee, Susana, Kaye, Stan

Volltext

Reversal of drug resistance in ovarian cancer: where do we go from here? von Kaye, Stan B

Volltext

Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research von Kipps, Emma, Tan, David S. P., Kaye, Stan B.

Volltext

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial von Sandhu, Shahneen K, MD, Schelman, William R, MD, Wilding, George, MD, Moreno, Victor, MD, Baird, Richard D, PhD, Miranda, Susana, BSc, Hylands, Lucy, BSc, Riisnaes, Ruth, FIBMS, Forster, Martin, PhD, Omlin, Aurelius, MD, Kreischer, Nathan, MSc, Thway, Khin, MD, Gevensleben, Heidrun, MD, Sun, Linda, PhD, Loughney, John, PhD, Chatterjee, Manash, PhD, Toniatti, Carlo, PhD, Carpenter, Christopher L, MD, Iannone, Robert, MD, Kaye, Stan B, Prof, de Bono, Johann S, Prof, Wenham, Robert M

Volltext

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial von Ledermann, Jonathan A, Prof, Embleton, Andrew C, MSc, Raja, Fharat, BMBCh, Perren, Timothy J, Prof, Jayson, Gordon C, Prof, Rustin, Gordon J S, Prof, Kaye, Stan B, Prof, Hirte, Hal, MD, Eisenhauer, Elizabeth, Prof, Vaughan, Michelle, MB, Friedlander, Michael, Prof, González-Martín, Antonio, MD, Stark, Daniel, MD, Clark, Elizabeth, BSc, Farrelly, Laura, MSc, Swart, Ann Marie, Prof, Cook, Adrian, MSc, Kaplan, Richard S, Prof, Parmar, Mahesh K B, Prof

Volltext

PARP Inhibitors in BRCA Gene-Mutated Ovarian Cancer and Beyond von Banerjee, Susana, Kaye, Stan

Volltext

Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in... von KAYE, Stan B, LUBINSKI, Jan, SAFRA, Tamar, VERGOTE, Ignace, WICKENS, Mark, LOWE, Elizabeth S, CARMICHAEL, James, KAUFMAN, Bella, MATULONIS, Ursula, ERN ANG, Joo, GOURLEY, Charlie, KARLAN, Beth Y, AMNON, Amit, BELL-MCGUINN, Katherine M, CHEN, Lee-May, FRIEDLANDER, Michael

Volltext

Rethinking ovarian cancer: recommendations for improving outcomes von Vaughan, Sebastian, Coward, Jermaine I., Bast, Robert C., Berchuck, Andy, Berek, Jonathan S., Brenton, James D., Coukos, George, Crum, Christopher C., Drapkin, Ronny, Etemadmoghadam, Dariush, Friedlander, Michael, Gabra, Hani, Kaye, Stan B., Lord, Chris J., Lengyel, Ernst, Levine, Douglas A., McNeish, Iain A., Menon, Usha, Mills, Gordon B., Nephew, Kenneth P., Oza, Amit M., Sood, Anil K., Stronach, Euan A., Walczak, Henning, Bowtell, David D., Balkwill, Frances R.

Volltext

Identifying prognostic signatures in the blood of ovarian cancer patients von Attard, Gerhardt, Kaye, Stan B

Volltext

Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers von Perkins, Geraldine, Yap, Timothy A, Pope, Lorna, Cassidy, Amy M, Dukes, Juliet P, Riisnaes, Ruth, Massard, Christophe, Cassier, Philippe A, Miranda, Susana, Clark, Jeremy, Denholm, Katie A, Thway, Khin, Gonzalez De Castro, David, Attard, Gerhardt, Molife, L Rhoda, Kaye, Stan B, Banerji, Udai, de Bono, Johann S

Volltext

Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval von FONG, Peter C, YAP, Timothy A, A'HERN, Roger, TUTT, Andrew, ASHWORTH, Alan, STONE, John, CARMICHAEL, James, SCHELLENS, Jan H. M, DE BONO, Johann S, KAYE, Stan B, BOSS, David S, CARDEN, Craig P, MERGUI-ROELVINK, Marja, GOURLEY, Charlie, DE GREVE, Jacques, LUBINSKI, Jan, SHANLEY, Susan, MESSIOU, Christina

Volltext

Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer von Attard, Gerhardt, Reid, Alison H M, A'Hern, Roger, Parker, Christopher, Oommen, Nikhil Babu, Folkerd, Elizabeth, Messiou, Christina, Molife, L Rhoda, Maier, Gal, Thompson, Emilda, Olmos, David, Sinha, Rajesh, Lee, Gloria, Dowsett, Mitch, Kaye, Stan B, Dearnaley, David, Kheoh, Thian, Molina, Arturo, de Bono, Johann S

Volltext

Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven von ATTARD, Gerhardt, REID, Alison H. M, CLARK, Jeremy, COOPER, Colin S, KAYE, Stan B, DEARNALEY, David, LEE, Gloria, DE BONO, Johann S, YAP, Timothy A, RAYNAUD, Florence, DOWSETT, Mitch, SETTATREE, Sarah, BARRETT, Mary, PARKER, Christopher, MARTINS, Vanessa, FOLKERD, Elizabeth

Volltext

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers von Fong, Peter C, Boss, David S, Yap, Timothy A, Tutt, Andrew, Wu, Peijun, Mergui-Roelvink, Marja, Mortimer, Peter, Swaisland, Helen, Lau, Alan, O'Connor, Mark J, Ashworth, Alan, Carmichael, James, Kaye, Stan B, Schellens, Jan H.M, de Bono, Johann S

Volltext

First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors von Sarker, Debashis, Ang, Joo Ern, Baird, Richard, Kristeleit, Rebecca, Shah, Krunal, Moreno, Victor, Clarke, Paul A, Raynaud, Florence I, Levy, Gallia, Ware, Joseph A, Mazina, Kathryn, Lin, Ray, Wu, Jenny, Fredrickson, Jill, Spoerke, Jill M, Lackner, Mark R, Yan, Yibing, Friedman, Lori S, Kaye, Stan B, Derynck, Mika K, Workman, Paul, de Bono, Johann S

Volltext

Ovarian cancer: progress and continuing controversies in management von Moss, Charlotte, Kaye, Stan B

Volltext